Exercise Training and Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01234155|
Recruitment Status : Completed
First Posted : November 4, 2010
Last Update Posted : December 3, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Behavioral: Exercise Training - Interval Walking Behavioral: Exercise - Continuous Walking||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||32 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||November 2014|
|No Intervention: Control|
|Experimental: Exercise - Continuous Walking||
Behavioral: Exercise - Continuous Walking
Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
|Experimental: Exercise - Interval Walking||
Behavioral: Exercise Training - Interval Walking
Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
- Glycemic Control [ Time Frame: 0 and 4 months ]Fasting glucose, two-hour glucose during OGTT, and hemoglobin A1c will be measured.
- Beta-cell Function [ Time Frame: 0 and 4 months ]Glucose tolerance tests and hyperglycemic clamps combined with GLP-1 / GIP will be conducted. Glucose tracer kinetics and C-peptide deconvolution will be used to assess pancreatic function.
- Body Composition [ Time Frame: 0 and 4 months ]DXA and MRI will be used to assess changes in whole body and regional adiposity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01234155
|Copenhagen, Denmark, 2100|
|Principal Investigator:||Thomas P Solomon, Ph.D.||Rigshospitalet, Denmark|
|Principal Investigator:||Kristian Karstoft, M.D.||Rigshospitalet, Denmark|